FAQ
Log In
Thursday 8th December 2016
News
 › 
 › 

Study of BCG vaccination

10th April 2006

A study by Trunz, Fine and Dye, published in The Lancet, assesses and compares the cost and effect of BCG as an intervention against severe childhood tuberculosis in different regions of the world.

BCG vaccine has shown consistently high efficacy against childhood tuberculous meningitis and miliary tuberculosis, but variable efficacy against adult pulmonary tuberculosis and other mycobacterial diseases.

The study concludes that BCG vaccination should be retained in high-incidence countries as a strategy to supplement the chemotherapy of active tuberculosis as it is a highly cost-effective intervention against severe childhood tuberculosis.

 

 

 

Share this page

Comments

There are no comments for this article, be the first to comment!


Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: Study of BCG vaccination
Author: Sue Knights
Article Id: 219
Date Added: 10th Apr 2006

Sources

The Lancet

Recent Related Articles

Animal TB threatens human health

Actions

Add to scrapbook
Show Comments
Add comment
Find all related articles

Tags

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2016